Messy. Lackluster. Weak. Those descriptions are rarely ascribed to earnings from Biogen Inc., but shares (NASDAQ:BIIB) of the Cambridge, Mass.-based company took a humbling blow after analysts hurled those adjectives, and more, at the company's second quarter report.